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Hydrolyzed formulas (HFs) are presently used primarily in infants that cannot be exclusively breastfed and those with documented cow's milk (CM) allergy, and for primary prevention of allergic disease. HFs are increasingly being used worldwide (table 1), begging the question if HFs may be recommended as the optimal choice for all standard-risk, fullterm infants who are not exclusively breastfed.
From the regulatory standpoint, all extensively HFs (eHFs) in the United States and Canada are approved for use only under physician supervision, thus not approved or commercialized for routine use in healthy infants. Only one of the partially HFs (pHFs) which contains 100% whey partially hydrolyzed with trypsin is approved, marketed and commercialized as a routine-use infant formula for healthy term infants. In Europe, eHFs fall under the category of food for special medical purposes, also meant for use under medical supervision, but pHFs in Europe have been commercialized for routine use for a number of years. However, the most recent directive from the European Food Safety Authority states that only pHFs containing 100% whey using a specific hydrolysis process are appropriate for use as routine formulas for healthy term infants.
Data regarding the nutritional adequacy of modern-day HFs are scarce and lack long-term data suggesting that growth in infants fed HF versus intact protein formula (IPF) is different. There may be theoretical concern that partially hydrolyzed protein is both absorbed and metabolized faster than intact protein; whether this has any impact on the health outcomes of infants is unknown, but available data from eHFs are reassuring.
While human breast milk is the optimal source of nutrition for multiple reasons, a 2006 systematic review determined there were no comparable long-term studies regarding the prolonged use of HFs versus breastfeeding [1] . There are studies, however, that have examined the use of various formulas as a primary source or supplement to reduce the risk of atopic disease. Meta-analyses of formula consumption and the risk of atopic dermatitis (AD) have found that infants fed pHF compared to Costeffectiveness There are sufficient data to suggest that pHF-W given to formula-fed infants at high risk for AD is costeffective for the prevention of AD in several countries
Studies not done for most HFs
The costs of formulas vary significantly among countries, making it difficult to incorporate this into a global decision-making process Table 2 .
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IPF had a lower risk of AD [2, 3] , but there are significant limitations to these studies, making conclusions about the general use of HFs problematic. Some of the strongest evidence for use of HFs for allergy prevention comes from the German Infant Nutritional Interventional (GINI) study, which followed 945 high-risk newborn infants in a randomized trial investigating the effects of breastfeeding supplemented with one of four formulas, CM, whey-based pHF (pHF-W), whey-based eHF (eHF-W) or casein-based eHF (eHF-C), in the first 4 months of life [4] . Feeding with either pHF-W or eHF-C had a preventive effect on the cumulative incidence of AD in high-risk children that lasted until 10 years, the current point of published data; however, it should be noted that the primary preventive effect on AD by using either pHF-W or eHF-C was seen within the first 2 years of life, with no significant change in effect in the remaining 8 years. Additional trials are needed in high-risk infants to confirm these findings.
Costs should be considered in decision-making regarding the choice of the formula, but global comparison of this is difficult given large cost differences in different countries. Data suggest that pHF given to infants who are not exclusively breastfed is a cost-effective intervention for the prevention of atopic disorders, such as AD [5] , though the question has been raised that the impact of allergy prevention in studies using HFs is limited to AD prevention, which implies that these preventive effects cannot be generalized to other allergic diseases in the atopic march, such as asthma and allergic rhinitis.
Despite the issues raised here (table 2) , the desire to provide concrete recommendations of widespread HF use needs to be assessed carefully so as not to overstate claims of benefit. Long-term studies are needed to investigate the feasibility of HF as a routine feeding option for healthy, standard-risk infants. Because of the paucity of data for pHFs or eHFs, the routine use of HFs for every infant as an equivalent option to breastfeeding or IPF cannot be supported at present based on available scientific evidence.
